Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)
Close on Nov 18, 2026Market cap $8.38BP/E –Yield –
Summit Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Summit Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $568.74M, up 63.2% year over year. For fiscal 2025 it was $537.67M, up 256.6% from the year before. The highest annual figure on record is $537.67M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $537.67M | +256.6% |
| FY2024 | Dec 31, 2024 | $150.78M | +153.5% |
| FY2023 | Dec 31, 2023 | $59.47M | +14.4% |
| FY2022 | Dec 31, 2022 | $52.00M | -39.1% |
| FY2021 | Dec 31, 2021 | $85.35M | +64.1% |
| FY2019 | Jan 31, 2019 | $52.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $157.73M | -24.2% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $132.62M | +158.7% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $147.29M | +186.7% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $131.10M | +247.5% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $208.02M | +575.4% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $51.27M | +66.1% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $51.38M | +107.1% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $37.72M | +146.2% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $30.80M | +225.9% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $30.87M | +212.4% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $24.81M | +360.7% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $15.32M | -10.1% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $9.45M | +4.9% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $9.88M | -51.9% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $5.39M | -76.7% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $17.05M | -14.5% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $9.01M | -62.3% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $20.56M | +11.8% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $23.11M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $19.94M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $23.92M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $18.38M | – |
See a number that looks wrong?